ImmuPharma (LON:IMM) Issues Earnings Results

ImmuPharma (LON:IMM) issued its quarterly earnings results on Tuesday. The company reported GBX (0.84) earnings per share (EPS) for the quarter, Digital Look Earnings reports. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 633.14%.

ImmuPharma Stock Performance

ImmuPharma stock opened at GBX 3.41 on Thursday. The business’s fifty day moving average is GBX 3.87 and its two-hundred day moving average is GBX 4.47. The firm has a market cap of £21.26 million, a P/E ratio of -9.21 and a beta of 3.01. ImmuPharma has a 52 week low of GBX 3.02 and a 52 week high of GBX 14.50.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.